Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients with High-Risk MDS [myelodysplastic syndromes] and AML [acute myeloid leukaemia].

Trial Profile

Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients with High-Risk MDS [myelodysplastic syndromes] and AML [acute myeloid leukaemia].

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2015

At a glance

  • Drugs Vorinostat (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 23 Jan 2013 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top